Jefferies stays Buy on Enanta Pharmaceuticals (ENTA) as co announces oral arguments for PFE patent case
Tweet Send to a Friend
Jefferies analyst Akash Tewari reiterated a Buy rating and $20.00 price target on Enanta Pharmaceuticals (NASDAQ: ENTA)The analyst commented, "ENTA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
